Clinical trial
Abaloparatide Added to Ongoing Denosumab vs Continued Denosumab Alone
NCT04467983 is registered in ClinicalTrials.gov with Hospital for Special Surgery, New York as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Abaloparatide Added to Ongoing Denosumab vs Continued Denosumab Alone
- Lead sponsor
- Hospital for Special Surgery, New York
- Phase
- Phase 4
- Overall status
- Active, not recruiting
- Start date
- February 1, 2021
- Completion date
- December 31, 2026
- Enrollment
- 70 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.